#DIA2018 | Alberto Grignolo on Expedited Pathways

July 2, 2018
From the floor at #DIA2018 - PAREXEL Corporate VP Alberto Grignolo shares his views on the proliferation of expedited regulatory approval pathways in key markets and its implications for global clinical development.
Previous Video
#DIA2018 | Alberto Grignolo on 4 Key Innovations
#DIA2018 | Alberto Grignolo on 4 Key Innovations

From the floor at #DIA2018 - PAREXEL Corporate VP Alberto Grignolo details the innovations referenced in th...

Next Video
#DIA2018 | Michelle Hoiseth on Real-World Data in Drug Development
#DIA2018 | Michelle Hoiseth on Real-World Data in Drug Development

From the floor at #DIA2018 - PAREXEL Corporate VP Michelle Hoiseth discusses the importance of Real-Word Da...